--- title: "Alto Neuroscience (ANRO) news: class action, IPO and offering" url: "https://aibio.space/companies/alto-neuroscience/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ANRO class action, IPO and offering news: Alto Neuroscience IPO securities class action dismissed with leave to amend. Alto Neuroscience, Inc." --- ANRO Alto Neuroscience, Inc. NYSE · United States # Alto Neuroscience (ANRO) news ANRO class action, IPO and offering news Legal · 2026-08-12 ## [Alto Neuroscience IPO securities class action dismissed with leave to amend](https://aibio.space/news/alto-neuroscience-ipo-securities-class-action-dismissed-leave-amend/) A federal court in California dismissed the securities class action over Alto Neuroscience's ALTO-100 disclosures on August 7, 2026, and gave the plaintiffs leave to file a third amended complaint. A related derivative action has been stayed. ## Latest Alto Neuroscience news 1. 2025-06-03 Mergers [Alto Neuroscience buys depression drug candidates from Chase Therapeutics, pays $1,750,000 upfront](https://aibio.space/news/alto-neuroscience-buys-depression-drug-candidates-chase-therapeutics/) Alto may owe up to $71,500,000 in milestone payments, payable in cash or restricted stock, and says its cash is still expected to fund operations into 2028. 2. 2025-02-03 Financings [Alto Neuroscience files $300,000,000 shelf with $75,000,000 at-the-market program](https://aibio.space/news/alto-neuroscience-files-300-000-000-shelf-75-000-000-market-program/) Alto Neuroscience filed a $300,000,000 shelf on February 3, 2025 and signed a $75,000,000 at-the-market sales agreement with Leerink Partners LLC, but no sale can start until the SEC declares the shelf effective, and its year-end cash figure is still preliminary. 3. 2025-01-16 Debt Financing [Alto Neuroscience amends K2 HealthVentures loan, $20.0 million funded and maturity now 2029](https://aibio.space/news/alto-neuroscience-amends-k2-healthventures-loan-20-0-million-funded/) Alto Neuroscience's January 13, 2025 amendment lifts the maximum term loans from $35.0 million to $75.0 million and moves maturity to January 1, 2029. Only $20.0 million was funded at signing, and about $10 million of that went to refinance the old loan and pay fees. ## Alto Neuroscience at a glance - **Ticker**: ANRO - **Listing**: NYSE - **Country**: United States - **Cash, Jun 30, 2026**: $243.7 million ### Related companies - [Zenas BioPharma](https://aibio.space/companies/zenas-biopharma/) NASDAQ: ZBIO - [Wave Life Sciences](https://aibio.space/companies/wave-life-sciences/) NASDAQ: WVE - [Marker Therapeutics](https://aibio.space/companies/marker-therapeutics/) NASDAQ: MRKR - [Contineum Therapeutics](https://aibio.space/companies/contineum-therapeutics/) NASDAQ: CTNM - [Enliven Therapeutics](https://aibio.space/companies/enliven-therapeutics/) NASDAQ: ELVN - [AVVAA World Health Care Products](https://aibio.space/companies/avvaa-world-health-care-products/) OTC: AVVH - [Unicycive Therapeutics](https://aibio.space/companies/unicycive-therapeutics/) NASDAQ: UNCY - [Voyager Therapeutics](https://aibio.space/companies/voyager-therapeutics/) NASDAQ: VYGR ### Also on NYSE - [Stereotaxis](https://aibio.space/companies/stereotaxis/) STXS - [Edwards Lifesciences](https://aibio.space/companies/edwards-lifesciences/) EW - [ADC Therapeutics SA](https://aibio.space/companies/adc-therapeutics/) ADCT - [HAEMONETICS CORP](https://aibio.space/companies/haemonetics/) HAE - [STERIS](https://aibio.space/companies/steris/) STE - [ARTIVION, INC.](https://aibio.space/companies/artivion/) AORT ## What Alto Neuroscience does Alto Neuroscience is a clinical-stage biopharmaceutical company that aims to redefine psychiatry through its Precision Psychiatry Platform, which discovers brain-based biomarkers to identify which patients are more likely to respond to its product candidates. The company has seven clinical-stage assets addressing major depressive disorder, bipolar depression, treatment resistant depression, schizophrenia and Parkinson's disease. Its most advanced program is ALTO-207, a fixed-dose combination of pramipexole and ondansetron that the company acquired in May 2025 from Chase Therapeutics Corporation. ALTO-207 is being developed for treatment resistant depression, and the company plans a Phase 2b trial. The platform collects data from neurocognitive assessments, electroencephalography, wearable devices and genetic samples, and applies machine learning. The company reports biomarker collection across more than 70 unique clinical sites and from over 2,000 participants. | Product or program | What it is | Stage | |---|---|---| | ALTO-207 | Fixed-dose pramipexole and ondansetron combination for treatment resistant depression | Phase 2b planned; Phase 3 expected to start by early 2027 | | Precision Psychiatry Platform | Brain biomarker discovery using EEG, neurocognitive assessments and wearable devices | biomarker collection across more than 70 unique clinical sites | Summarised from the company's [10-K filed Mar 16, 2026](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000002/alto-20251231.htm). ## Alto Neuroscience annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$45.6 million](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000002/) | [$47.0 million](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000002/) | | Net income (loss) | [-$63.2 million](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000002/) | [-$61.4 million](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000002/) | | Cash from operations | [-$51.8 million](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000002/) | [-$47.4 million](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000002/) | | Cash and equivalents | [$176.5 million](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000023/) | [$168.2 million](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000002/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $243.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Analysis - Opinion Mixed view 2026-10-28 [Alto has about $338 million pro forma, but two Phase 2 trials missed and burn is rising](https://aibio.space/analysis/alto-has-cash-now-but-burn-rising-runway-claim-thin/) Alto reports $243.7 million, plus $94.6 million net from a July offering. Our arithmetic gives 43 to 59 months. But ALTO-100 and ALTO-101 both missed in Phase 2, and quarterly spending is up sharply. Opinion, not personal investment advice. [All analysis](https://aibio.space/analysis/). ## Questions about Alto Neuroscience Is there a class action against Alto Neuroscience? Our latest story on this, dated Aug 12, 2026: "Alto Neuroscience IPO securities class action dismissed with leave to amend". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/alto-neuroscience-ipo-securities-class-action-dismissed-leave-amend/). When did Alto Neuroscience go public? Our latest story on this, dated Aug 12, 2026: "Alto Neuroscience IPO securities class action dismissed with leave to amend". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/alto-neuroscience-ipo-securities-class-action-dismissed-leave-amend/). Has Alto Neuroscience raised money recently? Our latest story on this, dated Feb 3, 2025: "Alto Neuroscience files $300,000,000 shelf with $75,000,000 at-the-market program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/alto-neuroscience-files-300-000-000-shelf-75-000-000-market-program/). What is the ticker symbol of Alto Neuroscience? Alto Neuroscience, Inc. trades under the ticker ANRO on NYSE. Where is Alto Neuroscience listed? Alto Neuroscience, Inc. is listed on NYSE. What is the SEC CIK of Alto Neuroscience? The SEC Central Index Key (CIK) for Alto Neuroscience, Inc. is 1999480. Its filings are on SEC EDGAR. How many shares does Alto Neuroscience have outstanding? 39,242,104 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Alto Neuroscience listed under? Our directory records Alto Neuroscience, Inc. under United States. What does Alto Neuroscience do? Our directory classifies Alto Neuroscience, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Alto Neuroscience? The ISIN recorded for Alto Neuroscience, Inc. is US02157Q1094. Does aibio.space cover Alto Neuroscience? aibio.space lists Alto Neuroscience, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Alto Neuroscience incorporated? SEC records list its state or country of incorporation as DE. What does Alto Neuroscience develop? Alto Neuroscience is a clinical-stage biopharmaceutical company that aims to redefine psychiatry through its Precision Psychiatry Platform, which discovers brain-based biomarkers to identify which patients are more likely to respond to its product candidates. The company has seven clinical-stage assets addressing major depressive disorder, bipolar depression, treatment resistant depression, schizophrenia and Parkinson's disease. What is ALTO-207 from Alto Neuroscience? ALTO-207: Fixed-dose pramipexole and ondansetron combination for treatment resistant depression Stage: Phase 2b planned; Phase 3 expected to start by early 2027. What is Precision Psychiatry Platform from Alto Neuroscience? Precision Psychiatry Platform: Brain biomarker discovery using EEG, neurocognitive assessments and wearable devices Stage: biomarker collection across more than 70 unique clinical sites. ## Investor discussion: Alto Neuroscience Members talk about Alto Neuroscience (ANRO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Alto Neuroscience, newest first. Each line links the filing it comes from. 1. 2026-07-14 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1999480/000110465926083268/tm2620333-1_424b5.htm) 2. 2026-03-16 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1999480/000110465926027953/tm268876d1_ex99-1.htm) 3. 2025-11-12 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000090/alto-20250930.htm) 4. 2025-10-20 Financings Reported a financing. SEC Form 8-K (Items 1.01,1.02,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1999480/000110465925100801/tm2529007d1_ex99-1.htm) 5. 2025-08-13 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000076/alto-20250630.htm) 6. 2025-06-03 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000048/exhibit991-pressrelease.htm) 7. 2025-02-03 Financings Reported a financing. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1999480/000119312525019267/d919606ds3.htm) 8. 2025-01-16 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1999480/000119312525007383/d891653d8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NYSE:ANRO on TradingView](https://www.tradingview.com/symbols/NYSE-ANRO/). ## SEC filings and registration - **SEC name**: Alto Neuroscience, Inc. - **CIK**: 1999480 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ANRO (NYSE) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW, CA, 94041 - **Phone**: 773-255-5012 - **Shares outstanding**: 39,242,104 as of 2026-08-07 (10-Q filed 2026-08-12) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000024/alto-20260826.htm) filed 2026-08-27 - [10-Q](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000023/alto-20260630.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000022/alto-20260812.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1999480/000110465926083274/tm2620328d1_8k.htm) filed 2026-07-14 - [424B5](https://www.sec.gov/Archives/edgar/data/1999480/000110465926083268/tm2620333-1_424b5.htm) filed 2026-07-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1999480/000110465926082875/tm2620297d1_8k.htm) filed 2026-07-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000016/alto-20260527.htm) filed 2026-05-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000014/alto-20260512.htm) filed 2026-05-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001999480), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Alto Neuroscience, Inc. is a public biotech or pharmaceutical company listed on NYSE under the ticker ANRO, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Alto Neuroscience, Inc. - **Ticker**: ANRO - **Listing**: NYSE - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US02157Q1094 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NYSE-ANRO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/alto-neuroscience/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Alto Neuroscience (ANRO) news: class action, IPO and offering", 2026-10-31, https://aibio.space/companies/alto-neuroscience/